367 related articles for article (PubMed ID: 24448212)
1. Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application.
Watkins CC; Sawa A; Pomper MG
Transl Psychiatry; 2014 Jan; 4(1):e350. PubMed ID: 24448212
[TBL] [Abstract][Full Text] [Related]
2. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
3. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
[TBL] [Abstract][Full Text] [Related]
4. Kinins and microglial responses in bipolar disorder: a neuroinflammation hypothesis.
Naaldijk YM; Bittencourt MC; Sack U; Ulrich H
Biol Chem; 2016 Apr; 397(4):283-96. PubMed ID: 26859499
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders.
Kozikowski AP; Gaisina IN; Yuan H; Petukhov PA; Blond SY; Fedolak A; Caldarone B; McGonigle P
J Am Chem Soc; 2007 Jul; 129(26):8328-32. PubMed ID: 17552518
[TBL] [Abstract][Full Text] [Related]
6. The Wnt signaling pathway in bipolar disorder.
Gould TD; Manji HK
Neuroscientist; 2002 Oct; 8(5):497-511. PubMed ID: 12374432
[TBL] [Abstract][Full Text] [Related]
7. Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascades.
Wang MJ; Huang HY; Chen WF; Chang HF; Kuo JS
J Neuroinflammation; 2010 Dec; 7():99. PubMed ID: 21194439
[TBL] [Abstract][Full Text] [Related]
8. Lithium and valproate act on the GSK-3β signaling pathway to reverse manic-like behavior in an animal model of mania induced by ouabain.
Valvassori SS; Dal-Pont GC; Resende WR; Jornada LK; Peterle BR; Machado AG; Farias HR; de Souza CT; Carvalho AF; Quevedo J
Neuropharmacology; 2017 May; 117():447-459. PubMed ID: 27789311
[TBL] [Abstract][Full Text] [Related]
9. Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder.
Soeiro-de-Souza MG; Dias VV; Figueira ML; Forlenza OV; Gattaz WF; Zarate CA; Machado-Vieira R
Acta Psychiatr Scand; 2012 Nov; 126(5):332-41. PubMed ID: 22676371
[TBL] [Abstract][Full Text] [Related]
10. Deficiency of diacylglycerol kinase η induces lithium-sensitive mania-like behavior.
Isozaki T; Komenoi S; Lu Q; Usuki T; Tomokata S; Matsutomo D; Sakai H; Bando K; Kiyonari H; Sakane F
J Neurochem; 2016 Aug; 138(3):448-56. PubMed ID: 27167678
[TBL] [Abstract][Full Text] [Related]
11. Postmortem evidence of brain inflammatory markers in bipolar disorder: a systematic review.
Giridharan VV; Sayana P; Pinjari OF; Ahmad N; da Rosa MI; Quevedo J; Barichello T
Mol Psychiatry; 2020 Jan; 25(1):94-113. PubMed ID: 31249382
[TBL] [Abstract][Full Text] [Related]
12. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons.
Hall AC; Brennan A; Goold RG; Cleverley K; Lucas FR; Gordon-Weeks PR; Salinas PC
Mol Cell Neurosci; 2002 Jun; 20(2):257-70. PubMed ID: 12093158
[TBL] [Abstract][Full Text] [Related]
13. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.
Rybakowski JK
CNS Drugs; 2013 Mar; 27(3):165-73. PubMed ID: 23378337
[TBL] [Abstract][Full Text] [Related]
14. [Mood stabilizers--past, present and future].
Sümegi A
Neuropsychopharmacol Hung; 2008 Mar; 10(1):31-42. PubMed ID: 18771018
[TBL] [Abstract][Full Text] [Related]
15. The role of Wnt signaling and its interaction with diverse mechanisms of cellular apoptosis in the pathophysiology of bipolar disorder.
Hu LW; Kawamoto EM; Brietzke E; Scavone C; Lafer B
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):11-7. PubMed ID: 20828594
[TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase-3β activity and cognitive functioning in patients with bipolar I disorder.
Munkholm K; Miskowiak KW; Jacoby AS; Vinberg M; Leme Talib L; Gattaz WF; Kessing LV
Eur Neuropsychopharmacol; 2018 Mar; 28(3):361-368. PubMed ID: 29433844
[TBL] [Abstract][Full Text] [Related]
17. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection.
Li X; Bijur GN; Jope RS
Bipolar Disord; 2002 Apr; 4(2):137-44. PubMed ID: 12071511
[TBL] [Abstract][Full Text] [Related]
18. Volume, metabolites and neuroinflammation of the hippocampus in bipolar disorder - A combined magnetic resonance imaging and positron emission tomography study.
Haarman BC; Burger H; Doorduin J; Renken RJ; Sibeijn-Kuiper AJ; Marsman JB; de Vries EF; de Groot JC; Drexhage HA; Mendes R; Nolen WA; Riemersma-Van der Lek RF
Brain Behav Immun; 2016 Aug; 56():21-33. PubMed ID: 26348581
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant therapies inhibit inflammation and microglial M1-polarization.
Kalkman HO; Feuerbach D
Pharmacol Ther; 2016 Jul; 163():82-93. PubMed ID: 27101921
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Glycogen Content in Astrocytes via Cav-1/PTEN/AKT/GSK-3β Pathway by Three Anti-bipolar Drugs.
Jia S; Li B; Huang J; Verkhratsky A; Peng L
Neurochem Res; 2018 Aug; 43(8):1692-1701. PubMed ID: 29968232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
